Literature DB >> 17023667

Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

Tomohito Ohtani1, Miho Ohta, Kazuhiro Yamamoto, Toshiaki Mano, Yasushi Sakata, Mayu Nishio, Yasuharu Takeda, Junichi Yoshida, Takeshi Miwa, Mitsuhiro Okamoto, Tohru Masuyama, Yasuki Nonaka, Masatsugu Hori.   

Abstract

Cardiac aldosterone levels have not been evaluated in diastolic heart failure (DHF), and its roles in this type of heart failure remain unclear. This study aimed to detect cardiac aldosterone by use of a liquid chromatographic-mass spectrometric method and to assess the effects of mineralocorticoid receptor blockade on hypertensive DHF. Dahl salt-sensitive rats fed 8% NaCl diet from 7 wk (hypertensive DHF model) were divided at 13 wk into three groups: those treated with subdepressor doses of eplerenone (12.5 or 40 mg x kg(-1) x day(-1)) and an untreated group. Dahl salt-sensitive rats fed 0.3% NaCl diet served as controls. Cardiac aldosterone was detected in the DHF rats but not in the control rats, with increased ventricular levels of mineralocorticoid receptor. Cardiac levels of 11-deoxycorticosterone, corticosterone, and 11-dehydrocorticosterone were not different between the control and DHF rats, but the tissue level of corticosterone that has an affinity to mineralocorticoid receptor was 1,000 times as high as that of aldosterone. Aldosterone synthase activity and CYP11B2 mRNA were undetectable in the ventricular tissue of the DHF rats. Administration of eplerenone attenuated ventricular hypertrophy, ventricular fibrosis, myocardial stiffening, and relaxation abnormality, leading to the prevention of overt DHF. In summary, the myocardial aldosterone level increased in the DHF rats. However, its value was extremely low compared with corticosterone, and no evidence for enhancement of intrinsic myocardial aldosterone production was found. The upregulation of mineralocorticoid receptor may play a central role in the pathogenesis of DHF, and blockade of mineralocorticoid receptor is likely an effective therapeutic regimen of DHF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023667     DOI: 10.1152/ajpregu.00402.2006

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  27 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 2.  Mineralocorticoid antagonism and cardiac hypertrophy.

Authors:  Kohzo Nagata
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Alessandra Dei Cas; Robert J Mentz; Stephen J Greene; Sadiya Khan; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Marvin A Konstam; Michele Senni; Gregg C Fonarow; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2014-06-24       Impact factor: 2.778

Review 4.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 5.  Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Kazuhiro Yamamoto
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

6.  Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".

Authors:  Selma F Mohammed; Tomohito Ohtani; Josef Korinek; Carolyn S P Lam; Katarina Larsen; Robert D Simari; Maria L Valencik; John C Burnett; Margaret M Redfield
Journal:  Circulation       Date:  2010-07-12       Impact factor: 29.690

7.  Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart.

Authors:  Celine Latouche; Yannis Sainte-Marie; Marja Steenman; Paulo Castro Chaves; Aniko Naray-Fejes-Toth; Geza Fejes-Toth; Nicolette Farman; Frederic Jaisser
Journal:  Endocrinology       Date:  2010-06-30       Impact factor: 4.736

8.  Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL).

Authors:  Yosuke Omori; Toshiaki Mano; Tomohito Ohtani; Yasushi Sakata; Yasuharu Takeda; Shunsuke Tamaki; Yasumasa Tsukamoto; Takeshi Miwa; Kazuhiro Yamamoto; Issei Komuro
Journal:  Yonago Acta Med       Date:  2014-10-15       Impact factor: 1.641

Review 9.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

10.  Extracellular superoxide dismutase ameliorates skeletal muscle abnormalities, cachexia, and exercise intolerance in mice with congestive heart failure.

Authors:  Mitsuharu Okutsu; Jarrod A Call; Vitor A Lira; Mei Zhang; Jean A Donet; Brent A French; Kyle S Martin; Shayn M Peirce-Cottler; Christopher M Rembold; Brian H Annex; Zhen Yan
Journal:  Circ Heart Fail       Date:  2014-02-12       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.